Phase I trial of next-generation srRNA rabies vaccine
Drug Discovery World
SEPTEMBER 15, 2023
Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. Rabies, RBI-4000 and the Phase I trial Rabies remains a public health threat in several geographical regions and is designated an NIAID Priority Pathogen.
Let's personalize your content